Navigation Links
Survival Benefit With Syndax Pharmaceuticals' Entinostat Maintained in Women with Advanced Breast Cancer
Date:12/7/2011

mestane + placebo HR = 0.58 (95%CI: 0.34, 0.97) p = 0.04
  • Progression-free survival: 4.3 months for exemestane + entinostat vs. 2.3 months for exemestane + placebo HR = 0.73 (95%CI: 0.49, 1.09) p = 0.06; 1-sided significance prospectively defined as  <0.10
  • Progression-free survival of 8.5 months for exemestane + entinostat in subset of patients with increased protein acetylaton vs. 2.8 months in non acetylators HR = 0.32 (95%CI: 0.13, 0.79)
  • Trend in improved progression-free survival in hormone-resistant vs. hormone-sensitive patients
  • Exemestane combined with entinostat was well tolerated with the most frequent adverse events consisting of fatigue, gastrointestinal disturbances and hematologic abnormalities
  • "The continued survival benefit increases our confidence that entinostat will play a critical role in the treatment of women with estrogen receptor-positive metastatic breast cancer," said Joanna Horobin, MD, president and chief executive officer of Syndax.  "We look forward to moving entinostat into phase 3 clinical testing in 2012."

    San Antonio Breast Cancer Symposium
    Presentation Date/Time: Wednesday, December 7 from 5:00 PM - 7:00 PM
    Poster Title: Entinostat, a Novel Histone Deacetylase Inhibitor, Added to Exemestane Improves PFS in Advanced Breast Cancer in a Randomized, Phase II, Double-Blind Study
    Session: POSTER DISCUSSION I: Endocrine Resistance
    Abstract Number: PD01-04
    Location: Ballroom A

    Breast Cancer and Hormone Therapy
    Approximately 230,000 new cases of invasive breast cancer are diagnosed in women annually in the United States and there are approximately 150,000 women living with metastatic breast cancer (MBC).  Over 70 percent of women with breast cancer have estrogen receptor-positive (ER+) breast cancer.  The most effective cancer treatments target the underlying biology and in breast canc
    '/>"/>

    SOURCE Syndax Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
    2. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
    3. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
    4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
    5. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
    6. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    7. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
    8. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
    9. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
    10. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
    11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
    (Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
    (Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
    Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
    (Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
    (Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
    (Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
    (Date:4/17/2014)... time online has the potential to ward off depression ... to research published online in The Journals ... . In the article " Internet Use and ... A Longitudinal Analysis ," the authors report that Internet ... 33 percent among their study sample. , Late-life ...
    (Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
    Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
    ... CHERRY HILL, N.J., Sept. 11 Nuvilex, Inc. (OTC ... its joint venture partner, has informed the company that ... its homeopathic remedy for helping to prevent and treat ... The Reme-Flu(TM) formula consists of a two-part protocol. ...
    ... Bupa,s Latin America and Caribbean,operation -- a division ... the launch of the international Ecuador Challenge, which will,take ... families survive on,average on just $4 a day. Some ... Ecuador until November 29 to build essential health and ...
    ... , MISSISSAUGA, Ontario, Sept. 11 JAG ... agreement with The Investor Relations Group, Inc. ("IRG"), pursuant to which ... the Company in accordance with the terms of the agreement. As ... to IRG. , , "We are very excited ...
    ... , , YARDLEY, Pa., Sept. 11 ... soft tissue and skeletal repair of the extremities, announced today that ... Chairman of the Board, effective immediately. , , ... as it moves from product development to commercialization," said Zev Scherl, ...
    ... , IRVING, Texas, Sept. 11 ... 643 on its third annual Inc. 5000, an exclusive ranking ... most comprehensive look at the most important segment of the ... rental car service Zipcar, and beverage maker Honest Tea are ...
    ... - HTDS www.htdsmedical.com The company is pleased ... Hope www.mellowhope.com has successfully completed and delivered ... Bangladesh. , In developing countries, over 11 million children ... nearly three quarters of these deaths result from infectious ...
    Cached Medicine News:Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 2Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 3Health News:Bupa Launches its 2009 International Charity Challenge to Help a Rural Community in Ecuador 2Health News:JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc. 2Health News:John C. Moran Named CEO at Core Essence Orthopaedics 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 3Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 4Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 5Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 6Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 7Health News:Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh 2Health News:Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh 3
    ... use in settings where a more secure band is ... but difficult to remove wristband is appropriate. The design ... time. One band to be placed on the wrist ... the first need to be replaced. This is particularly ...
    IDENTI-MATCH II is a combination of the IDENTI-MATCH Blood Recipient Identification System and an admitting band. It has been designed for those facilities using label-based patient ID systems....
    Zebras H 2824-Z Healthcare Starter Kit includes everything you need to start printing wristbands today: the H 2824-Z direct thermal printer, a pre-installed Media Adapter Guide, and a roll of adult-s...
    ... VerdaSees Navigaton™ software facilitates real time ... two modules: the first module is ... reader devices and the database where ... second module is the user interface, ...
    Medicine Products: